Publicacións nas que colabora con Eliecer Coto García (21)

2015

  1. A labor and cost effective next generation sequencing of PKHD1 in autosomal recessive polycystic kidney disease patients

    Gene, Vol. 561, Núm. 1, pp. 165-169

  2. ABCB1 (MDR-1) pharmacogenetics of tacrolimus in renal transplanted patients: A Next Generation Sequencing approach

    Clinical Chemistry and Laboratory Medicine, Vol. 53, Núm. 10, pp. 1515-1519

  3. The donor ABCB1 (MDR-1) C3435T polymorphism is a determinant of the graft glomerular filtration rate among tacrolimus treated kidney transplanted patients

    Journal of Human Genetics, Vol. 60, Núm. 5, pp. 273-276

2014

  1. A labor- and cost-effective non-optical semiconductor (Ion Torrent) next-generation sequencing of the SLC12A3 and CLCNKA/B genes in Gitelman's syndrome patients

    Journal of Human Genetics, Vol. 59, Núm. 7, pp. 376-380

  2. Effect of the FTO rs9930506 Polymorphism on the Main Comorbidities of the Cardiorenal Metabolic Syndrome in an Elderly Spanish Cohort

    CardioRenal Medicine, Vol. 4, Núm. 2, pp. 82-87

  3. Farmacogenética del tacrolimus: ¿del laboratorio al paciente?

    Nefrologia, Vol. 34, Núm. 1, pp. 11-17

  4. Mitochondrial DNA haplogroups and risk of new-onset diabetes among tacrolimus-treated renal transplanted patients

    Gene, Vol. 538, Núm. 1, pp. 195-198

2013

  1. A CLCNKA polymorphism (rs10927887; p.Arg83Gly) previously linked to heart failure is associated with the estimated glomerular filtration rate in the RENASTUR cohort

    Gene, Vol. 527, Núm. 2, pp. 670-672

  2. A common APOE polymorphism is an independent risk factor for reduced glomerular filtration rate in the Spanish RENASTUR cohort

    CardioRenal Medicine, Vol. 3, Núm. 2, pp. 113-119

  3. A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renal-transplanted patients

    Pharmacogenetics and Genomics, Vol. 23, Núm. 8, pp. 445-448

  4. Association between a MYH9 polymorphism (rs3752462) and renal function in the Spanish RENASTUR cohort

    Gene, Vol. 520, Núm. 1, pp. 73-76

2012

  1. Association between a common KCNJ11 polymorphism (rs5219) and new-onset posttransplant diabetes in patients treated with Tacrolimus

    Molecular Genetics and Metabolism, Vol. 105, Núm. 3, pp. 525-527

  2. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation

    Transplantation Proceedings

  3. Resequencing the whole MYH7 gene (including the intronic, promoter, and 3′ UTR sequences) in hypertrophic cardiomyopathy

    Journal of Molecular Diagnostics, Vol. 14, Núm. 5, pp. 518-524

2011

  1. Erratum: Pharmacogenetics of tacrolimus after renal transplantation: Analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes (Clinical Chemistry and Laboratory Medicine (2011) 49:5 (825-833))

    Clinical Chemistry and Laboratory Medicine

  2. KCNQ1 gene variants and risk of new-onset diabetes in tacrolimus-treated renal-transplanted patients

    Clinical Transplantation, Vol. 25, Núm. 3

  3. Pharmacogenetics of tacrolimus after renal transplantation: Analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes

    Clinical Chemistry and Laboratory Medicine, Vol. 49, Núm. 5, pp. 825-833

  4. Pharmacogenetics of tacrolimus: Ready for clinical translation

    Kidney International Supplements, Vol. 1, Núm. 2, pp. 58-62

2010

  1. Functional polymorphisms in genes of the Angiotensin and Serotonin systems and risk of hypertrophic cardiomyopathy: AT1R as a potential modifier

    Journal of Translational Medicine, Vol. 8

  2. Functional polymorphisms in the CYP3A4, CYP3A5, and CYP21A2 genes in the risk for hypertension in pregnancy

    Biochemical and Biophysical Research Communications, Vol. 397, Núm. 3, pp. 576-579